NCT06137638 is a Phase 2 clinical trial of ENA-001 in Respiratory Depression, sponsored by Enalare Therapeutics Inc..

Who is sponsoring NCT06137638?

NCT06137638 is sponsored by Enalare Therapeutics Inc..

What drugs are being tested in NCT06137638?

Interventions in NCT06137638: ENA-001.

What condition does NCT06137638 study?

NCT06137638 studies Respiratory Depression.

Is NCT06137638 still recruiting?

NCT06137638 is currently not yet recruiting. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT06137638

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ENA-001 for Post Operative Respiratory Depression (PORD)

Not yet recruiting Phase 2 Last updated 27 February 2026

What this trial tests

Phase 2 trial testing ENA-001 in Respiratory Depression in 200 participants. Not yet recruiting.

Timeline

15 December 2026

Primary endpoint
15 June 2027

15 July 2027

Quick facts

Lead sponsor	Enalare Therapeutics Inc.
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	200
Start date	15 December 2026
Primary completion	15 June 2027
Estimated completion	15 July 2027

Drugs / interventions tested

ENA-001 — full drug profile →

Conditions studied

Respiratory Depression — all drugs for Respiratory Depression →

Sponsor

Enalare Therapeutics Inc. — full company profile →

Who can join

18 and older, any sex, with Respiratory Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a Phase II, randomized, placebo-controlled, double-blind trial in 200 subjects having general anesthesia for major elective surgery with postoperative pain management to evaluate the efficacy, safety and tolerability of ENA-001 as a therapy to prevent post operative respiratory depression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ENA-001

Trials testing the same drug.

NCT06967259 — ENA-001 for Opioid Induced Respiratory Depression · Phase 1 · active not recruiting

Other recruiting trials for Respiratory Depression

Currently open trials in the same condition.

NCT07166614 — Dexmedetomidine vs Propofol in High-Risk ERCP Patients · NA · recruiting
NCT06967259 — ENA-001 for Opioid Induced Respiratory Depression · Phase 1 · active not recruiting
NCT06823661 — Transcutaneous Electrical Stimulation for Apnea Detected by Capnography · NA · recruiting
NCT06777758 — Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments · Phase 4 · recruiting
NCT06772961 — Effect of Percutaneous Electrical Acupoint Stimulation on the Improvement of Incidence of Adverse Respiratory Events · NA · recruiting

Other Enalare Therapeutics Inc. trials

Trials by the same sponsor.

NCT06967259 — ENA-001 for Opioid Induced Respiratory Depression · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06137638 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Enalare Therapeutics Inc.
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06137638.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing